title: Phosphate-binding capacity of ferrihydrite versus calcium acetate in rats.
abstract: Calcium salts, such as calcium carbonate and calcium acetate, are the principal compounds used as phosphate binders in patients with chronic renal failure. The dose required is three to six times the normal requirement for calcium. Use of these large doses of calcium salts in the diet can result in hypercalcemia. Other compounds have been investigated as phosphate binders with varying degrees of success. Synthetic ferrihydrite (5Fe(2)O(3).9H(2)O) has a high adsorptive capacity for phosphate and may be an effective phosphate binder. The phosphate-binding capacity of ferrihydrite was compared with that of calcium acetate in 250-g male Sprague Dawley rats. After an overnight fast, rats (n = 5 per group) were gavaged with an American Institute of Nutrition (AIN) 76 formula containing one third the daily phosphorus intake labeled with phosphorus-32 ((32)P). Either two levels of calcium acetate, representing three (1/2X) or six (1X) times the usual calcium intake for one third of the day, or equivalent amounts of ferrihydrite were added to the diet. An additional group received two times (2X) the larger dose, and a sixth control group received no binder in the diet. Phosphorus absorption curves were determined from (32)P appearance in the serum. The 1/2X dose of ferrihydrite reduced (32)P by approximately one half, and the 2X dose nearly completely suppressed (32)P absorption, similar to the 1X dose of calcium acetate. The advantage of using a ferrihydrite binder would be to avoid the hypercalcemia resulting from the use of high-dose calcium salts. An added advantage may result from the small amounts of iron absorbed in these chronically iron-deficient patients.
authors.affiliation: Department of Foods and Nutrition and Agronomy, Purdue University, West Lafayette, IN, USA. weavercm@cfs.purdue.edu
authors.forename: C M
authors.initials: CM
authors.lastname: Weaver
authors.forename: D G
authors.initials: DG
authors.lastname: Schulze
authors.forename: L W
authors.initials: LW
authors.lastname: Peck
authors.forename: H M
authors.initials: HM
authors.lastname: Magnusen
authors.forename: B R
authors.initials: BR
authors.lastname: Martin
authors.forename: S E
authors.initials: SE
authors.lastname: Gruenhagen
mesh_terms: D000042:Absorption; D000085:Acetates / Q000627:therapeutic use*; D000818:Animals; D017610:Calcium Compounds; D004305:Dose-Response Relationship, Drug; D005290:Ferric Compounds; D005293:Ferritins / Q000627:therapeutic use*; D008297:Male; D010710:Phosphates / Q000097:blood*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000085:Acetates; D017610:Calcium Compounds; D005290:Ferric Compounds; D010710:Phosphates; C092844:ferric oxyhydroxide; D005293:Ferritins; C120662:calcium acetate